Company & Sponsor Intelligence

Neurim Pharmaceuticals Ltd.

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials5

Recruiting0

Completed3

Countries2

Therapeutic footprint

alzheimersautism

Indexed studies

NCT04233502Efficacy and Safety of Slenyto for Insomnia in Children With ASD
autism · PHASE3

NCT01903681Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances
autism · NetherlandsPHASE1

NCT02615002Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)
alzheimers · United StatesPHASE2

NCT05267535Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
alzheimers · United StatesPHASE2, PHASE3

NCT00940589Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
alzheimers · United StatesPHASE2

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →